Interval Intraocular Pressure in Intravitreal Injection Study
Conditions:   Glaucoma;   Intraocular Pressure Interventions:   Drug: Timolol;   Drug: Travatan;   Drug: Hypromellose Sponsor:   The University of Hong Kong Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 30, 2021 Category: Research Source Type: clinical trials

Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
Conditions:   Primary Open Angle Glaucoma;   Ocular Hypertension Interventions:   Drug: QLS-101;   Drug: Timolol Maleate Sponsor:   Qlaris Bio, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2021 Category: Research Source Type: clinical trials

Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
Conditions:   Ocular Surface Disease;   Primary Open Angle Glaucoma Intervention:   Drug: Tafluprost, timolol maleate Sponsor:   Santen Pharmaceutical (Taiwan) Co., LTD Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2021 Category: Research Source Type: clinical trials

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Conditions:   Primary Open Angle Glaucoma;   Ocular Hypertension Interventions:   Drug: DE-126 Ophthalmic Solution 0.002% QD;   Drug: Timolol Maleate Ophthalmic Solution 0.5% BID Sponsor:   Santen Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2021 Category: Research Source Type: clinical trials

Comparative Study of the Efficacy of Either Krytantek Ofteno PF ® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.
Conditions:   Glaucoma, Open-Angle;   Ocular Hypertension Interventions:   Drug: Dorzolamide-timolol-brimonidine and latanoprost;   Drug: Dorzolamide-timolol and latanoprost Sponsor:   Laboratorios Sophia S.A de C.V. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 11, 2021 Category: Research Source Type: clinical trials

Beta-adrenergic antagonist for the healing of chronic diabetic foot ulcers: study protocol for a prospective, randomized, double-blinded, controlled and parallel-group study
This study will examine the efficacy and safety of topically applied beta-antagonist Timoptic-XE® (timolol maleate ophthalmic gel forming so lution) in subjects with DFUs.Methods/designThis is a phase two, randomized, double-blinded, controlled, and parallel-group clinical trial with two treatment arms, SOC plus topical Timoptic-XE ® and SOC plus a non-biologically active gel (hydrogel, as placebo drug). Study subjects with a DFU will be selected from the Veterans Affairs Northern California Health Care System (VANCHCS). Study duration is up to 31 weeks, with three phases (screening phase for two weeks, acti...
Source: Trials - June 7, 2020 Category: Research Source Type: clinical trials